Natera president Fesko sells $63,715 in stock

John Fesko, President and Chief Business Officer at Natera, Inc. (NASDAQ:NTRA), sold 339 shares of common stock on October 21, 2025, for $187.95, totaling $63,715. The transaction comes as Natera’s stock trades near its 52-week high, having delivered an impressive 53% return over the past year. According to InvestingPro analysis, the company currently appears overvalued at its $25.94B market capitalization.

Following the transaction, Fesko directly owns 152,408 shares of Natera.

The sale was to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs) and was executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c). The sale was executed pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person’s Stock Unit Agreement granted on January 28, 2022.

The transaction was reported in a Form 4 filing with the Securities and Exchange Commission.

The filing was signed by Vincent Fontanilla, Attorney-in-Fact, on October 22, 2025.

In other recent news, Natera has been actively advancing its medical research and technology. The company announced that it has enrolled over 1,600 patients in its EXPAND trial, a study evaluating its Fetal Focus single gene noninvasive prenatal test. This trial aims to confirm test results through prenatal or postnatal diagnostic testing with a diverse participant base. Additionally, Natera’s Signatera test demonstrated strong performance in monitoring uterine cancer and outperformed standard markers in predicting outcomes for testicular cancer patients, as revealed in studies published in the Journal of Clinical Oncology - Precision Oncology.

In terms of analyst coverage, Canaccord Genuity maintained a Buy rating with a $200 price target for Natera, emphasizing the company’s leadership in molecular residual disease testing. Meanwhile, Wells Fargo resumed coverage with an Equal Weight rating and set a price target of $175, highlighting Natera’s strong position in cell-free DNA testing technology. These developments reflect Natera’s ongoing efforts to reinforce its position in the medical field and its potential impact on various health markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.